The WHO has approved a post-2015 Global End Tuberculosis Strategy for tuberculosis (TB) 41 3 6
Phenotypic and molecular drug resistance detection 1 3 7
Phenotypic DST and GenotypeMTBDRplus (hereafter, MTBDRplus) were routinely 1 3 8
performed by the staff at the NRL (3) and results were anonymized, documented in 1 3 9
electronic data files and sent to the KIT. An optimized version (29) of the standard VNTR typing using 24 loci (30) was performed at 1 4in gyrA. MLPA detected the rrs-1401 mutation associated with resistance to 2 0 2 KAN/AMK/Capreomycin in 10 of the 399 isolates (three of which were XDR, and four MDR 2 0 3 by DST). In one of the 399 isolates, strain 12-15893, MLPA detected a mutation in the eis 2 0 4 gene, this strain was XDR by DST (TABLE A4) MTBDRplus assay was performed directly on sputum whereas the MLPA assay was 2 4 2 exclusively performed on cultured isolates. The MLPA assay was performed on site by the 2 4 3 local laboratory staff for monitoring purposes at the end of the month and not as a routine 2 4 4 tool such as the MTBDRplus assay which is performed on a daily basis. Minor problems 2 4 5 were experienced, mainly related to the stability/functionality of the Luminex MAGPIX device 2 4 6 but none of these prevented the assay from being performed always yielding good quality 2 4 7 data. However the analysis and interpretation of the data required remote support. Either 2 4 8 straight forward data analysis and interpretation or timely online support is a prerequisite for 2 4
and Beijing K1) accounted for 84% of all the MDR-TB identified. Additionally 29% (28/95) of 2 8 0 all Beijing K1 lineage strains and 79% (34/43) of all Beijing V+/CHIN+ strains were MDR. All 2 8 1 XDR-TB isolates identified were members of the Beijing lineage ( Figure 4 Although an MDR phenotype was associated with retreatment, Mtb lineage was much more 2 9 1 strongly associated in this data set. After univariate analyses individuals infected with a 2 9 2
Beijing strain had 20-fold higher odds (21.63, 95% CI 10.30 to 54.54) of being MDR-TB than 2 9 3 individuals infected with a Euro-American strain; whereas retreatment patients had a 4-fold 2 9 4
higher odds of being infected with an MDR-TB (4.59; 95% CI 2.68 to 7.68) (TABLE 3 and 2 9 5 FIGURE 4). Multivariate analysis confirmed that the effects of Beijing strain and retreatment 2 9 6
were independent (TABLE 3). 2 9 7 2 9 8
High Mtb cluster rates among previously hospitalized HIV patients co-infected with XDR-TB 2 9 9
(10) and reported TB infection among hospital workers suggests nosocomial transmission as 3 0 0 a main factor facilitating transmission of drug resistant strains. A high incidence of MDR-TB 3 0 1 strains in penitentiary systems (39), transmission of these strains in the community through 3 0 2 released inmates, prison staff and visitors (40) might also facilitate spread of MDR-TB 3 0 3 strains in high burden MDR-TB countries. Of all strains with any drug resistance identified by DST 32.0% (63/192) were streptomycin 3 0 6 monoresistant. The Euro-American lineage was over represented in the streptomycin-3 0 7 monoresistant strains, 85.2% 52 out of 61 were from the Euro-American lineage. Of these 52 3 0 8 streptomycin monoresistant isolates 13 (25%) belonged to the MLVA 15-9 type 769-15. This 3 0 9
MIRU type was identified in Georgia and named Georgia H37Rv-like (5, 24); indicating that a 3 1 0 proportion of the ancestors of the circulating Euro-American strains "witnessed" streptomycin 3 1 1 and their progeny are still circulating. lineage data with available DST and patient characteristics here strikingly demonstrated that 3 1 6 multidrug resistance is significantly more associated with the Beijing lineage than a previous 3 1 7 history of TB treatment in Georgia. To objectively measure the relative contribution of cross
Combining resistance and genotyping data with patient characteristics will become 3 2 4 increasingly practical to implement. A combined approach of spatial and molecular with 3 2 5 classical epidemiology to study the transmission of (MDR)-TB has been shown to be feasible 3 2 6
in Georgia. Infection control as well as treatment and patient management could benefit from 3 2 7 additional knowledge of the infecting Mtb lineages (41, 42) and aid the identification of 3 2 8 outbreak strains that might otherwise be missed (43). Most strikingly in this pilot 3 2 9 implementation, when the genotyping patient data and susceptibility data were combined it 3 3 0 was observed that a patient infected with a Beijing strain had 20-fold higher odds of being 3 3 1 MDR-TB than a patient infected with a Euro-American strain. Interestingly a retreatment 3 3 2 case of TB had "only" a 4-fold higher odds of being MDR-TB than a primary case. Monitoring 3 3 3 these associations could help to understand the local transmission dynamics and identify 3 3 4 areas where resources should be targeted. TB control programs can directly use genotyping 3 3 5 data, and in the future WGS data, to rationally develop, adapt and prioritize infection control 3 3 6 efforts but only if it is rapidly integrated with patient and bacteriological data: Such a goal is 3 3 7 becoming increasingly necessary but also realistic. The TB-MLPA as described in the text is commercially available as the TB-SNPID assay, 3 4 1 distributed via Beamedex, Orsay, France (www.beamedex.com). KIT BR has a financial 3 4 2 interest in the assay. 
